Prospects for the future of epidermal growth factor receptor-tyrosine kinase inhibitors in combination with bevacizumab.
作者信息
Chikaishi Yasuhiro, Tanaka Fumihiro, Honda Yohei, Inoue Masaaki, Yoshida Junichi, Tanaka Masao
机构信息
Department of Chest Surgery, Shimonoseki City Hospital, Kouyouchou, Shimonoseki, Japan.
Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Yahatanishi-ku, Kitakyushu, Japan.
出版信息
Transl Cancer Res. 2020 Mar;9(3):1307-1310. doi: 10.21037/tcr.2020.01.24.
Abstract
摘要
相似文献
1
Prospects for the future of epidermal growth factor receptor-tyrosine kinase inhibitors in combination with bevacizumab.表皮生长因子受体-酪氨酸激酶抑制剂与贝伐单抗联合应用的未来前景
Transl Cancer Res. 2020 Mar;9(3):1307-1310. doi: 10.21037/tcr.2020.01.24.
2
Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.化疗或酪氨酸激酶抑制剂联合贝伐单抗与单纯化疗或酪氨酸激酶抑制剂治疗非小细胞肺癌的疗效和安全性：一项系统评价和荟萃分析
Med Oncol. 2015 Feb;32(2):473. doi: 10.1007/s12032-014-0473-y. Epub 2015 Jan 21.
3
A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109).一项贝伐珠单抗联合卡铂和紫杉醇治疗表皮生长因子受体（EGFR）突变的一线 EGFR 酪氨酸激酶抑制剂治疗失败的非鳞状非小细胞肺癌患者的 II 期研究（HANSHIN Oncology Group 0109）。
Lung Cancer. 2015 Feb;87(2):136-40. doi: 10.1016/j.lungcan.2014.12.007. Epub 2014 Dec 19.
4
BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer.贝弗利：一项随机开放标签III期试验的原理与设计，该试验比较了贝伐单抗联合厄洛替尼与单纯厄洛替尼作为表皮生长因子受体（EGFR）突变的晚期非鳞状非小细胞肺癌患者一线治疗方案的疗效。
Clin Lung Cancer. 2016 Sep;17(5):461-465. doi: 10.1016/j.cllc.2016.04.001. Epub 2016 Apr 22.
5
Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.下一代 EGFR-TKIs 在非小细胞肺癌患者中的疗效：一项随机对照试验的荟萃分析。
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820940426. doi: 10.1177/1533033820940426.
6
Factors associated with efficacy of first-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.第一代表皮生长因子受体酪氨酸激酶抑制剂治疗非小细胞肺癌疗效的相关因素
Tumour Biol. 2017 May;39(5):1010428317705340. doi: 10.1177/1010428317705340.
7
Rationale and Design of a Randomized Phase 2 Trial of Gefitinib Plus Bevacizumab vs Gefitinib Alone in Patients with Epidermal Growth Factor Receptor Mutant Non-Squamous Non-Small-Cell Lung Cancer: Study Protocol.吉非替尼联合贝伐单抗对比吉非替尼单药治疗表皮生长因子受体突变的非鳞状非小细胞肺癌患者的随机2期试验的原理与设计：研究方案
Kurume Med J. 2019 May 16;65(2):77-81. doi: 10.2739/kurumemedj.MS652001. Epub 2018 Nov 15.
8
Combination strategies based on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for cancer patients: Pooled analysis and subgroup analysis of efficacy and safety.基于表皮生长因子受体（EGFR）酪氨酸激酶抑制剂的癌症患者联合治疗策略：疗效与安全性的汇总分析及亚组分析
Medicine (Baltimore). 2019 Mar;98(13):e14135. doi: 10.1097/MD.0000000000014135.
9
Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.用于表皮生长因子受体基因突变阳性非小细胞肺癌的酪氨酸激酶抑制剂：治疗学最新进展
J Oncol Pharm Pract. 2016 Jun;22(3):461-76. doi: 10.1177/1078155215577810. Epub 2015 Apr 8.
10
Is epidermal growth factor receptor tyrosine kinase inhibitor in combination with cytotoxic chemotherapy a better treatment option for patients with EGFR-mutated non-small-cell lung cancer?表皮生长因子受体酪氨酸激酶抑制剂联合细胞毒化疗是否为表皮生长因子受体突变型非小细胞肺癌患者的更佳治疗选择？
Transl Lung Cancer Res. 2016 Feb;5(1):98-101. doi: 10.3978/j.issn.2218-6751.2015.08.14.
本文引用的文献
1
Phase I/II Study of Osimertinib With Bevacizumab in EGFR-mutated, T790M-positive Patients With Progressed EGFR-TKIs: West Japan Oncology Group 8715L (WJOG8715L).奥希替尼联合贝伐珠单抗治疗 EGFR 突变、T790M 阳性经 EGFR-TKI 治疗进展的患者的 I/II 期研究：西日本肿瘤组 8715L（WJOG8715L）。
Clin Lung Cancer. 2019 Jul;20(4):e492-e494. doi: 10.1016/j.cllc.2019.03.002. Epub 2019 Mar 19.
2
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.厄洛替尼联合贝伐珠单抗对比厄洛替尼单药治疗表皮生长因子受体阳性的晚期非鳞状非小细胞肺癌（NEJ026）：一项开放标签、随机、多中心、III 期临床试验的期中分析。
Lancet Oncol. 2019 May;20(5):625-635. doi: 10.1016/S1470-2045(19)30035-X. Epub 2019 Apr 8.
3
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.阿替利珠单抗联合贝伐珠单抗和化疗治疗非小细胞肺癌（IMpower150）：一项随机、开放标签的 3 期临床试验中具有 EGFR 突变或基线肝转移患者的关键亚组分析。
Lancet Respir Med. 2019 May;7(5):387-401. doi: 10.1016/S2213-2600(19)30084-0. Epub 2019 Mar 25.
4
Rationale and Design of a Phase II Trial of Osimertinib Combined With Bevacizumab in Patients With Untreated Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer and Malignant Pleural and/or Pericardial Effusion (SPIRAL II Study).奥希替尼联合贝伐珠单抗治疗未经治疗的表皮生长因子受体突变型非小细胞肺癌伴恶性胸腔和/或心包积液患者的 II 期临床试验的原理和设计（SPIRAL II 研究）。
Clin Lung Cancer. 2019 May;20(3):e402-e406. doi: 10.1016/j.cllc.2019.02.016. Epub 2019 Feb 27.
5
Gefitinib Plus Bevacizumab . Gefitinib Alone for Mutant Non-squamous Non-small Cell Lung Cancer.吉非替尼联合贝伐单抗对比单用吉非替尼治疗突变型非鳞状非小细胞肺癌
In Vivo. 2019 Mar-Apr;33(2):477-482. doi: 10.21873/invivo.11498.
6
Effect of erlotinib plus bevacizumab on brain metastases in patients with non-small cell lung cancer.厄洛替尼联合贝伐单抗对非小细胞肺癌患者脑转移的影响。
Ann Transl Med. 2018 Oct;6(20):401. doi: 10.21037/atm.2018.09.33.
7
Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: Multicenter, single-arm, phase 2 trial (ABC Study).阿法替尼联合贝伐珠单抗治疗 EGFR 突变型非小细胞肺癌获得性耐药：多中心、单臂、Ⅱ期临床试验（ABC 研究）。
Cancer. 2018 Oct 1;124(19):3830-3838. doi: 10.1002/cncr.31678. Epub 2018 Sep 7.
8
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.未经治疗的表皮生长因子受体（EGFR）突变型晚期非小细胞肺癌患者中，中枢神经系统（CNS）对奥希替尼与标准表皮生长因子受体酪氨酸激酶抑制剂的反应。
J Clin Oncol. 2018 Aug 28:JCO2018783118. doi: 10.1200/JCO.2018.78.3118.
9
Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).非小细胞肺癌（NSCLC）中的免疫检查点抑制剂（ICIs）。
J UOEH. 2018;40(2):173-189. doi: 10.7888/juoeh.40.173.
10
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.奥希替尼治疗未经治疗的 EGFR 突变型晚期非小细胞肺癌。
N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18.
Zotero 插件